Novo Nordisk Resubmits Label Expansion Application to the US FDA for Semaglutide (2.0mg)
Shots:
- The company has announced the resubmission of a label expansion application to the US FDA for the existing marketing authorization for Ozempic to introduce a new dose of 2.0mg for the Treatment of T2D
- The resubmission follows the Refusal to File letter received by the FDA on 22 March 2021. The standard review time by the FDA is 10mos.
- The company has submitted the label expansion application in Jan’2021- based on the P-III results that showed a significant decline in HbA1c compared to semaglutide (1.0mg) in patients with T2D
Ref: Globe Newswire | Image: Scrip- Informa PLC
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com